Kevin Joseph Fitzgerald Sells 663 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the sale, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Tuesday, February 18th, Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $250.51 on Thursday. The business’s fifty day moving average price is $253.89 and its 200 day moving average price is $263.20. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The stock has a market capitalization of $32.43 billion, a PE ratio of -115.44 and a beta of 0.35. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.94 EPS for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $637,000. Focus Partners Advisor Solutions LLC acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $203,000. Worldquant Millennium Advisors LLC increased its position in Alnylam Pharmaceuticals by 156.6% in the fourth quarter. Worldquant Millennium Advisors LLC now owns 150,191 shares of the biopharmaceutical company’s stock worth $35,341,000 after buying an additional 91,671 shares during the period. Zurich Insurance Group Ltd FI acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $6,583,000. Finally, Vident Advisory LLC increased its position in Alnylam Pharmaceuticals by 21.2% in the fourth quarter. Vident Advisory LLC now owns 1,327 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 232 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a report on Tuesday. StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Raymond James upped their price target on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Barclays upped their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Finally, Scotiabank decreased their price target on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $299.48.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.